| MLM |
Report |
Total Revenue (continuing operations) |
BEAT |
pred ~$1.95B vs. cons $1.87B |
MEDIUM |
| MLM |
Report |
Adjusted EBITDA (continuing operations) |
BEAT |
pred ~$675M vs. cons ~$650M |
MEDIUM |
| MLM |
Report |
GAAP diluted EPS (continuing operations) |
MISS |
pred ~$4.35 vs. cons $4.62 |
MEDIUM |
| MLM |
Guide |
FY2026 Adjusted EBITDA guidance (raised to include NFM/Quikrete full-quarter run-rate) |
BETTER |
guide ~$2.48B vs. cons ~$2.45B (FY2026) |
MEDIUM |
| MLM |
Guide |
FY2026 Revenue guidance |
BETTER |
guide ~$7.30B vs. cons ~$7.20B (FY2026) |
MEDIUM |
| MLM |
Guide |
FY2026 Net earnings guidance (GAAP, continuing ops) |
LOWER |
guide ~$1.08B vs. cons ~$1.15B (FY2026) |
MEDIUM |
| MLM |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| MLM |
Return |
5-day cumulative residual |
+0.4% (FADE) |
The EBITDA/revenue beat and NFM-inclusive guide raise are largely pre-flagged (Nye teed up the upgrade at Q1) so much of the good news is priced, setting up a sell-the-news dynamic; VMC's Q2 print a day earlier (beat but no guide raise, weather/asphalt drag in overlapping TX/Southeast markets) is a cautionary read-through that could pressure MLM's own volume/margin commentary. A likely GAAP EPS miss (Lhoist deal costs, NFM step-up amortization, rising interest expense) creates a negative optics headline even if adjusted metrics beat, and the unresolved Lhoist leverage/dilution/integration overhang (Street PTs already cut on deal pricing) gets no new resolving information on the call - out-period net-earnings guidance likely trails the EBITDA raise as financing costs build into H2, pulling estimate revisions back down after an initial relief pop. |
LOW |